OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.

Authors

Joohyuk Sohn

Division of Medical Oncology, Yonsei Cancer Center, Seoul, South Korea

Joohyuk Sohn , Barbara Pistilli , Meritxell Bellet , Lucia Del Mastro , Heather L. McArthur , Jane Lowe Meisel , Peter Schmid , Rachel Wei , Arlene Chan , Elisabeth de Kermadec

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).

First Author: Erica L. Mayer

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor in patients with locally advanced or metastatic breast cancer: Initial results from a phase II study.

First Author: Tamta Makharadze

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER+/HER2- metastatic breast cancer (MBC).

First Author: Antonio Llombart-Cussac

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).

First Author: Mario Campone